We are evaluating the etiology, and we will continue to closely monitor safety in our PGN-EDO51 clinical program. We look forward to providing clinical data updates from both CONNECT1 and our ...

is accelerating a new clinical program aimed at tackling one of the largest challenges in contact lens wear—discomfort-related dropout. Building on promising clinical and in-vitro results ...

Clinical and Program Updates: Patient dosing in the Phase 2 portion of the Phase 2/3 study was completed on May 8, 2025. End-of-study follow-up assessments are expected to conclude by May 17 ...

Moving forward, the company will continue advancing the clinical program for danuglipron (PF-06882961), subject to results from the ongoing Phase 2 trial, and discontinue the clinical development ...